What is Franziska Michor’s total Recursion (RXRX) Class A share ownership after this grant?

After receiving the grant of 88,424 restricted stock units , Franziska Michor directly holds 215,477 Class A Common Stock shares of Recursion Pharmaceuticals. This total reflects her direct ownership position following the reported compensation-related transaction.

Recursion (NASDAQ: RXRX) director gets 88,424 restricted stock units

Q: What did Recursion Pharmaceuticals (RXRX) director Franziska Michor receive in this Form 4 filing?

Director Franziska Michor received a grant of 88,424 restricted stock units of Recursion Pharmaceuticals Class A Common Stock. This award was made under the company’s Outside Director Compensation Policy as stock-based compensation, not as an open-market share purchase.

Q: How and when do Franziska Michor’s new Recursion (RXRX) restricted stock units vest?

The 88,424 restricted stock units will vest on the earlier of June 17, 2027 or the day before Recursion’s 2027 Annual Meeting of Stockholders. Vesting is conditioned on Michor’s continued service as an outside director to the company.

Q: Is the Recursion (RXRX) Form 4 transaction a buy or a compensation grant?

The transaction is a compensation grant , not an open-market buy. It is coded as an “A” transaction, described as a grant or award acquisition of restricted stock units automatically issued under the Outside Director Compensation Policy.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Michor Franziska reported acquisition or exercise transactions in this Form 4 filing.

Recursion Pharmaceuticals director Franziska Michor received a grant of 88,424 restricted stock units of Class A Common Stock as compensation under the company’s Outside Director Compensation Policy. The units were granted at $0.00 per share, reflecting a stock-based award rather than an open-market purchase.

The restricted stock units will vest on the earlier of June 17, 2027 or the day prior to Recursion’s 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, Michor directly holds 215,477 shares of the company’s Class A Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Michor Franziska

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	88,424	$0.00	--

Holdings After Transaction: Class A Common Stock — 215,477 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Restricted stock units granted: 88,424 units Grant price per share: $0.00 per share Shares owned after transaction: 215,477 shares +2 more

5 metrics

Restricted stock units granted 88,424 units Award of Class A Common Stock RSUs to director

Grant price per share $0.00 per share RSU grant under Outside Director Compensation Policy

Shares owned after transaction 215,477 shares Director’s direct Class A Common Stock holdings post-grant

Vesting date trigger June 17, 2027 Latest vesting date for RSUs, or day before 2027 annual meeting

Transaction date June 17, 2026 Date RSU grant was reported

Key Terms

restricted stock units, Outside Director Compensation Policy, Annual Meeting of Stockholders, grant, award, or other acquisition

4 terms

restricted stock units financial

"Represents a grant of restricted stock units automatically granted pursuant"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Outside Director Compensation Policy financial

"automatically granted pursuant to the Issuer's Outside Director Compensation Policy"

Annual Meeting of Stockholders financial

"the day prior to the Issuer's 2027 Annual Meeting of Stockholders"

grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/22/2026 - 10:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Michor Franziska

(Last)

(First)

(Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

UTAH

84101

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/17/2026		A⁽¹⁾		88,424	A	$0	215,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Recursion Pharmaceuticals (RXRX) director Franziska Michor receive in this Form 4 filing?

Director Franziska Michor received a grant of 88,424 restricted stock units of Recursion Pharmaceuticals Class A Common Stock. This award was made under the company’s Outside Director Compensation Policy as stock-based compensation, not as an open-market share purchase.

How and when do Franziska Michor’s new Recursion (RXRX) restricted stock units vest?

The 88,424 restricted stock units will vest on the earlier of June 17, 2027 or the day before Recursion’s 2027 Annual Meeting of Stockholders. Vesting is conditioned on Michor’s continued service as an outside director to the company.

Did Franziska Michor pay cash for the Recursion (RXRX) shares reported in this Form 4?

No cash changed hands for this award. The Form 4 lists a transaction price of $0.00 per share, indicating these shares were granted as restricted stock units under a compensation policy rather than purchased in the open market.

Is the Recursion (RXRX) Form 4 transaction a buy or a compensation grant?

The transaction is a compensation grant, not an open-market buy. It is coded as an “A” transaction, described as a grant or award acquisition of restricted stock units automatically issued under the Outside Director Compensation Policy.